Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel peptide-based HIV-1 immunotherapy.

Maja A Sommerfelt1, Jørgen Nyhus, Birger Sørensen

  • 1Bionor Immuno AS, Strømdaljordet 4, PO Box 1823 Gulset, NO-3703 Skien, Norway. Maja.sommerfelt@bionorimmuno.com

Expert Opinion on Biological Therapy
|March 10, 2004
PubMed
Summary

Therapeutic immunization using peptides can enhance highly active antiretroviral therapy for HIV-1. This approach leverages advanced bioinformatics and dendritic cells for potent T cell stimulation against diverse viral strains.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influenza-A mediated pre-existing immunity levels to SARS-CoV-2 could predict early COVID-19 outbreak dynamics.

iScience·2023
Same author

Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity.

QRB discovery·2021
Same author

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.

PloS one·2019
Same author

Postvaccination C-Reactive Protein and C5/gp41<sup>732-744</sup> Antibody Level Fold-Changes Over Baseline Are Independent Predictors of Therapeutic HIV Vaccine Effect in a Phase 2 Clinical Study of Vacc-4x.

AIDS research and human retroviruses·2018
Same author

A novel peptide-based vaccine candidate with protective efficacy against influenza A in a mouse model.

Virology·2017
Same author

Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial.

EBioMedicine·2017

Area of Science:

  • Immunology
  • Virology
  • Biotechnology

Background:

  • Highly active antiretroviral therapy (HAART) is standard for HIV-1 infection.
  • Therapeutic immunization strategies are needed to augment HAART.
  • Peptide-based immunotherapies offer safety advantages over conventional methods.

Purpose of the Study:

  • To explore peptide-based immunotherapeutic strategies for HIV-1.
  • To investigate the use of bioinformatics in designing effective T cell epitopes.
  • To evaluate the potential of dendritic cells in delivering peptide immunotherapeutics.

Main Methods:

  • Utilizing advanced bioinformatics to analyze T cell epitopes and human leukocyte antigen (HLA) presentation.
  • Designing peptides targeting conserved viral domains for broad reactivity.

Related Experiment Videos

  • Employing dendritic cells for peptide administration and cross-presentation.

    • Main Results:

    • Sophisticated peptide design enables analysis of T cell epitopes and HLA class I/II presentation.
    • Targeting conserved viral domains enhances peptide reactivity against diverse HIV-1 strains.
    • Dendritic cells facilitate cross-presentation of exogenous peptides on HLA class I and II.

    Conclusions:

    • Peptide-based immunotherapeutics are a promising, safe approach to augment HAART for HIV-1.
    • Bioinformatics tools are crucial for designing effective peptide immunogens.
    • Dendritic cell administration enables robust CD4+ and CD8+ T cell responses through cross-presentation.